Loading…
Medicare Access to Rural Anesthesiology Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Medicare Access to Rural Anesthesiology Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to provide Medicare payment on a reasonable-cost basis for anesthesia services furnished by an anesthesiologist in a rural hospital. Specifically, the CMS shall provide payment for such services in the same manner as payment is provided under current law for services furnished in a rural hospital by a certified registered nurse anesthetist.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · first_quarter · Medicare/Medicaid
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2024 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP); Medicaid Best Price Policy; Medicaid - Centers for Medicare & Medicaid Services notice of proposed rulemaking: "Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program."
Referred to the House Committee on Ways and Means.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $2,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2023 Budget and Appropriations Legislation; Medicaid drug rebate program; Medicaid - Centers for Medicare & Medicaid Services notice of proposed rulemaking: "Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program."
Client expense: $1,940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; FY-2023 Budget and Appropriations Legislation; Medicaid drug rebate program.
Client expense: $2,130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Medicare/Medicaid
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; FY-2023 Budget and Appropriations Legislation.
Client expense: $2,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE